Kryptos Biotechnologies, a Silicon Valley-based startup developing a diagnostics platform for cancer at a single-cell level, has snapped up $2.7 million in pre-series A round funding.
The funding came from Seoul-based investment firms FuturePlay, Coolidge Corner Investment and KDB Capital.
The latest round adds to Krpytos Biotechnologies’ $2.6 million early-stage funding from angel investors and companies including LG Chem and BAPartners.
Kryptos Biotechnologies COO Lee Jin-yong (left) and CEO Son Jun-ho
The funding will be used to accelerate commercialization of its platform, Kryptos co-founder and CEO Son Jun-ho said.
Founded in 2017 in Hayward, California, by scientist Son and former management consultant Lee Jin-yong, Kryptos has been advancing its platform that allows scientists and clinicians to make the right clinical decision. With its single-cell ultrafast photonic polymerase chain reaction, the technology will capture the genuine status of each cell to present unbiased genomic characteristics, which Kryptos says will improve accuracy of the diagnosis.
“A clinical diagnosis of tissues has had limitations to diagnose cancer,” said FuturePlay CEO Ryu Jung-hee, who led the pre-series A round. “Kryptos’ technology will enable the human race to find clues for early detection of cancer.”
By Son Ji-hyoung (firstname.lastname@example.org)